硝苯啶对慢性肺心病急发期血小板功能的机理探讨

THE EFFECTS OF NIFEDIPINE ON PLATELET FUNCTION IN PATIENTS WITH CHRONIC PULMONARY HEART DISEASE

本文对35例肺心病急发期患者进行血小板功能的研究,随机分为A、B两组,A组18例,男11例,女7例,平均年龄64±9岁;B组17例,男12例,女5例,平均年龄66±7岁,A组加用硝苯啶(Nif)10mg3次/d,在治疗前及治疗一周后用放免法分别测定血小板表面α-颗粒膜蛋白(GMP-140)、TXB_2(TXA_2的稳定代谢终产物)、6-Keto-PGF_1(?)(PGI_2的稳定代谢终产物).结果表明:肺心病组GMP-140、TXB_2、TXB_2/6-Keto-PGF较正常组明显升高(P<0.001).A组在治疗一周后 GMP-140水平较B组明显下降(P<0.05),说明Nif具有抑制血小板活化的作用.

The paper has studied the effects of nifedipine on platelet function in patients with chronic pulmonary heart disease during acute stage, 35 patients entered a randomized trial. The same general treatment was given in group A and group B, and the one-week regime of nifedipine (30mg/day ,oral) in group A. α-granul membrane protein of platelets(GMP-140). TXB2 and 6-Ke-to-PGF10(the stable metabolites of TXA2 and PGI2),blood platelet counter (BPC), blood gas analysis were measured in 35 patients before and after one-week treatment. The results show that the number of GMP-140 molecules on platelet surface was significantly higher than those observed in normal subjects(P<0. 01). After treatment, a significant decrease of the number of GMP-140 molecules was observed in the group A,while no change was seen in the group B. It's suggested that nifedipine may antagonize platelet activation.